Prescription drug · ANDA
Ethambutol Hydrochloride NDC 70518-3662
Ethambutol hydrochloride 100 mg/1 · Tablet · Oral · REMEDYREPACK INC.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70518-3662-1 | 70518366201 | 50 POUCH in 1 BOX (70518-3662-1) / 1 TABLET in 1 POUCH (70518-3662-2)Marketed from Apr 23, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ethambutol Hydrochloride
- Generic name (nonproprietary)
- ethambutol hydrochloride
- Active ingredients
- Ethambutol hydrochloride — 100 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- REMEDYREPACK INC.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 078939
- Marketing start
- Listing expires
- Identifiers
- Product ID 70518-3662_5905d3ca-1eac-bdff-e063-6394a90a51e6SPL ID 5905d3ca-1eac-bdff-e063-6394a90a51e6SPL set ID e0d4a594-d3e0-47b0-9f11-f4dbd4552d5aRxCUI 995599UNII QE4VW5FO07
- Pharmacologic class
- Antimycobacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470518366201followed by a unit qualifier and the quantityPackage 70518-3662-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. In patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: Ethambutol plus isoniazid Ethambutol plus isoniazid plus streptomycin. In patients who have received previous antituberculous therapy, mycobacterial …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 078939
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ethambutol Hydrochloride | Ethambutol hydrochloride 400 mg/1 | TabletOral | REMEDYREPACK INC. | 70518-2966 |
| Ethambutol Hydrochloride | Ethambutol hydrochloride 400 mg/1 | TabletOral | American Health Packaging | 68084-280 |
| Ethambutol Hydrochloride | Ethambutol hydrochloride 100 mg/1 | TabletOral | Lupin Pharmaceuticals, Inc. | 68180-280 |
| Ethambutol Hydrochloride | Ethambutol hydrochloride 400 mg/1 | TabletOral | Lupin Pharmaceuticals, Inc. | 68180-281 |